- About
- Projects
- Column 1
- Animal Health & Veterinary Medicine
- Expanded Access
- FDA Patient Listening Sessions
- Food & Nutrition
- Column 2
- Column 1
- News and Events
- Expanded Access eRequest
Coverage
Accordingly, NRX-100 is available for expanded access to eligible patients. More about this program can be learned from the Reagan Udall Foundation, https://navigator.reaganudall.org/, which works in conjunction with the FDA to provide public…
The Reagan-Udall Foundation (RUF) has issued “Roadmap to Produce Safety: Summary Report of the Produce Safety Dialogue,” a report commissioned by the U.S. Food and Drug Administration recommending the implementation of a shared-responsibility approach…
The Reagan Udall Foundation (RUF) Report: Roadmap to Produce Safety, released July 28, 2025, is centered on the tenet that fresh produce safety is a shared responsibility. If responsibility is truly shared, then so must be the accountability—for both…
Hyman, Phelps & McNamara, P.C.’s John Gilbert will be speaking at the Demand Forecasting for Controlled Substances Hybrid Public Meeting sponsored by the Reagan-Udall Foundation for the FDA, Washington, DC. on August 27, 2025.
Food Safety Matters Podcast: The Future of Food Regulation Under MAHA
The Reagan-Udall Foundation for the FDA (RUF) has issued its FDA-commissioned report, Roadmap to Produce Safety: Summary Report of the Produce Safety Dialogue. Summing up RUF’s “produce safety dialogue” with more than 170 stakeholders in the produce…
The Reagan-Udall Foundation (RUF) for the FDA released its Roadmap to Produce Safety: Summary Report of the Produce Safety Dialogue.
On July 23, the Reagan-Udall Foundation, in cooperation with FDA, held a public meeting to gather input on the clinical use and safety concerns associated with orally ingestible unapproved prescription drug products containing fluoride for use in…
The Reagan-Udall Foundation (RUF) has released its Roadmap to Produce Safety: Summary of the Produce Safety Dialogue, which reflects input from produce sector stakeholders and is intended to serve as a “foundation for transformative change in produce…
FDA’s new Rare Disease Innovation Hub and Office of Regulatory and Emerging Diseases are addressing some of the issues, but neither has the resources nor authority to comprehensively approach the unique patient impact of chronic progressive diseases. A…